Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SELLAS Life Sciences Group, Inc. - Common Stock (NQ:SLS)

2.230 +0.030 (+1.36%)
Streaming Delayed Price Updated: 11:40 AM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about SELLAS Life Sciences Group, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
SELLAS Life Sciences Stock Has Doubled This Year – Here’s Why Retail Investors Are Bullish ↗
The results from the company’s Phase 2 clinical trial for the investigational drug SLS009 and the Phase 3 REGAL trial, a survival-driven study of galinpepimut-S (GPS), are garnering interest. 
Via Stocktwits
Topics Death
News headline image
SELLAS Life Sciences Draws Retail Buzz On SLS009 Trial Momentum – Stock Soars In Pre-Market ↗
The trial involved combining SLS009 with azacitidine and venetoclax in patients with relapsed or refractory acute myeloid leukemia. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Papa John's Is Not First: Here Are 3 Other Stocks Rocked By Market-Moving Fake News ↗
Papa John's (PZZA) stock surged from a fake news hoax. It's not the first. See 3 other stocks, like Vinci & Avon, hit by market scams. 
Via Benzinga
Why Is SELLAS Life Sciences Stock Falling Today? ↗
Via Stocktwits
News headline image
These stocks are moving in today's after hours session ↗
Let's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
Sellas Life Sciences Stock Jumps Over 7% Premarket: Buzz Builds Ahead Of Weekend Cancer Drug Presentation In Berlin ↗
The company said its cancer drug SLS009 showed strong preclinical results in T-cell prolymphocytic leukemia, improving survival and reducing tumor burden both alone and in combination with venetoclax. 
Via Stocktwits
News headline image
SELLAS Life Sciences Stock Rises On Strong Preclinical Data For Investigational Cancer Treatment ↗
SELLAS said that in a study model, SLS009 monotherapy and the combination prolonged overall survival compared to Venetoclax alone, with a statistically significant difference. 
Via Stocktwits
News headline image
Sellas Life Sciences Stock In Spotlight After Institutional Investor Exercises Existing Warrants ↗
In consideration for the immediate exercise of the warrants in full, the institutional investor will receive new, unregistered warrants in a private placement to purchase up to 19.69 million shares of... 
Via Stocktwits
News headline image
SELLAS Life Sciences Group Inc (NASDAQ:SLS) Reports Q2 2025 Earnings: Narrower Loss and Clinical Progress Amid Revenue Challenges ↗
SELLAS Life Sciences (SLS) reported Q2 2025 EPS of -$0.07, beating estimates, with no revenue. Cash position strengthened to $25.3M. Clinical trials progress highlighted, including REGAL Phase 3 AML... 
Via Chartmill
News headline image
Thursday's after hours session: top gainers and losers ↗
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Top movers in Tuesday's after hours session ↗
The US market regular session of Tuesday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
News headline image
Wondering what's happening in today's after-hours session? ↗
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
What's going on in today's after hours session ↗
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
These stocks are moving in today's session ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
8 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
SLS Stock Earnings: SELLAS Life Sciences Gr Beats EPS for Q2 2024 ↗
SLS stock results show that SELLAS Life Sciences Gr beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q1 2024 ↗
SLS stock results show that SELLAS Life Sciences Gr missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q4 2023 ↗
SLS stock results show that SELLAS Life Sciences Gr missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Dow Falls Over 200 Points; Adobe Shares Plunge ↗
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 200 points on Friday. The Dow traded down 0.55% to 38,692.43 while the NASDAQ fell 0.90% to 15,982.65. The S&P... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates. 
Via Benzinga
News headline image
Crude Oil Edges Lower; US Consumer Sentiment Falls In March ↗
U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 100 points on Friday. The Dow traded down 0.37% to 38,761.74 while the NASDAQ fell 0.95% to 15,974.83. The S&P 500... 
Via Benzinga
Topics Stocks
News headline image
Nasdaq Down Over 100 Points; Hibbett Reports Downbeat Sales ↗
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 100 points on Friday. Following the market opening Friday, the Dow traded down 0.28% to 38,797.24 while the NASDAQ... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Zijin Mining Invests $97M In Solaris Resources, Deal To Bolster Copper Project In Ecuador ↗
China-based Zijin Mining is investing $97 million in Solaris Resources. Proceeds will go toward an Ecuador-based project. 
Via Benzinga
News headline image
Crude Oil Moves Lower; Walgreens Posts Upbeat Earnings ↗
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining over 100 points on Thursday. The Dow traded up 0.33% to 37,554.56 while the NASDAQ fell 0.10% to 14,578.04. The S&P... 
Via Benzinga
Topics Stocks
News headline image
Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.< 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.